White Paper

Quantification Of Vector Genomic DNA And Residual DNA In Gene Therapy Vectors Using ddPCR

Source: Thermo Fisher Scientific

By Sushma A. Ogram, Small Scale and Assay Development and Analytics, Head, Thermo Fisher Scientific

DNA sequence, DNA code

Capitalizing on advances in science and technology to help cure cancer and genetic diseases has led to significant growth of the cell and gene therapy (CGT) market. With so many CGT products in the pipeline today, as well as high success rates for those in clinical trials, the FDA anticipates it will be approving 10 to 20 CGT products a year by 2025.1 A key component of bringing these life-saving drugs to market is the production of viral vectors that are used to deliver the therapeutic gene. However, this requires efficient and scalable manufacturing strategies, which currently stands as one of the biggest barriers for commercialization of CGT products. One area where there is a significant need for improvement in this field is analytical testing methods, which are used to determine the safety, strength, and purity of viral vectors.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: